Gabagamma, 300 mg, 50 pcs.

Active substance:

gabapentin 300 mg;

Excipients :

lactose;

corn starch;

talc;

gelatin;

titanium dioxide;

iron oxide yellow;

iron oxide red

• complex therapy of partial seizures with or without secondary generalization in adults and children from 12 years of age;
• pain syndrome in diabetic neuropathy;
• postherpetic neuralgia in adults.

• hypersensitivity to any of the components of the drug;
• acute pancreatitis;
• hereditary galactose deficiency;
• lactase deficiency;
• glucose-galactose malabsorption.

Precautions: renal failure; psychotic diseases.

Cardiovascular system: symptoms of vasodilation or increased blood pressure, palpitations.

Digestive tract: flatulence, anorexia, gingivitis, abdominal pain, constipation, dental disease, diarrhea, dyspepsia, increased appetite, dry mouth or throat, nausea, vomiting, dental disease, increased activity of hepatic transaminases, hepatitis, jaundice, pancreatitis.

Blood system, lymphatic system: purpura (most often it is described as bruising that occurred during physical trauma), leukopenia, thrombocytopenia.

Musculoskeletal system: arthralgia, back pain, increased fragility of bones, myalgia.

Nervous system: dizziness; headache, hyperkinesis, muscle dyskinesia and dystonia, choreoathetosis, increased, weakened or absent reflexes; dysarthria, ataxia, nystagmus, paresthesia, convulsions, confusion, increased fatigue, asthenia, amnesia, depression, impaired thinking, hostility, emotional lability, insomnia, anxiety, drowsiness, hallucinations.

Respiratory system: pneumonia, bronchitis, shortness of breath, respiratory infections, cough, pharyngitis, rhinitis.

Skin and subcutaneous tissue: acne, pruritus, skin rash, peripheral edema, erythema multiforme exudative (including Steven-Johnson syndrome).

Genitourinary system: urinary tract infection, impotence, urinary incontinence, acute renal failure.

Sense organs: visual impairment, amblyopia, diplopia, tinnitus, otitis media.

Other: fever, viral infection, weight gain, plasma glucose lability in patients with diabetes mellitus, pain of various localization.

Morphine: when gabapentin and morphine were taken together, when morphine was taken 2 hours before gabapentin, an average AUC of gabapentin was increased by 44% compared with gabapentin monotherapy, which was associated with an increase in the pain threshold (cold pressor test). The clinical significance of this change has not been established; the pharmacokinetic characteristics of morphine have not changed. Side effects of morphine when taken together with gabapentin did not differ from those when taking morphine in conjunction with placebo.

The interaction between gabapentin and phenobarbital, phenytoin, valproic acid and carbamazepine was not observed. The pharmacokinetics of gabapentin in equilibrium are the same in healthy people and patients receiving other anticonvulsants.

The simultaneous use of gabapentin with oral contraceptives containing norethindrone and / or ethinyl estradiol was not accompanied by changes in the pharmacokinetics of both components.

The simultaneous use of gabapentin with antacids containing aluminum and magnesium is accompanied by a decrease in the bioavailability of gabapentin by about 20%. Gabapentin is recommended to be taken approximately 2 hours after taking antacid.

Probenecid does not affect renal excretion of gabapentin.

A slight decrease in renal excretion of gabapentin while taking cimetidine probably does not have clinical significance.

Inside, regardless of the meal or with food.

If it is necessary to reduce the dose, cancel the drug or replace it with an alternative agent, this should be done gradually over a period of at least one week.

Neuropathic pain in adults

The initial dose is 900 mg / day in 3 divided doses; if necessary, the dose is gradually increased to a maximum of 3600 mg / day. Treatment can begin immediately with a dose of 900 mg / day (300 mg 3 times a day) or during the first three days the dose can be gradually increased to 900 mg / day according to the following scheme: on the 1st day - 300 mg of the drug 1 time per day; on the 2nd day - 300 mg 2 times a day; on the 3rd day - 300 mg 3 times a day. You can also use a dosage of 400 mg for patients who are either overweight or are above average growth, similar to titrating a dosage of 300 mg.

Partial convulsions in adults and children from 12 years of age

The effective dose is from 900 to 3600 mg / day. Therapy can be started with a dose of 300 mg 3 times a day on the first day or gradually increased to 900 mg according to the scheme described above (see "Neuropathic pain in adults"). Subsequently, the dose can be increased to 3600 mg / day (divided into 3 equal doses). The maximum interval between doses with a 3-fold administration of the drug should not exceed 12 hours in order to avoid the resumption of seizures.

There is no need to control the concentration of gabapentin in plasma. It can be used in combination with other anticonvulsant drugs without taking into account changes in its plasma concentration or the concentration of other antiepileptic drugs in serum.

Symptoms: dizziness, diplopia, speech impairment, drowsiness, lethargy, diarrhea, and increased severity of other side effects.

Treatment: gastric lavage, the appointment of activated carbon, symptomatic therapy. Patients with severe renal failure may be shown hemodialysis.

Although withdrawal syndrome with the development of seizures was not noted in the treatment with gabapentin, nevertheless, a sharp cessation of antiepileptic therapy in patients with partial seizures can provoke the development of seizures (see "Dosage and administration").

Gabapentin is not considered an effective treatment for abscess epilepsy.

In patients who require joint therapy with morphine, an increase in the dose of gabapentin may be required. At the same time, it is necessary to carefully monitor patients for the development of such a sign of central nervous system depression as drowsiness. In this case, the dose of gabapentin or morphine should be adequately reduced (see "Interaction with other drugs").

Laboratory research. When gabapentin was added to other anticonvulsants, false-positive results were detected when urine protein was detected using Ames N-Multistix SG ^® test strips . To determine the protein in the urine, it is recommended to use a more specific method of precipitation with sulfosalicylic acid.

Influence on the ability to drive a car and use machinery. Patients should avoid driving, as well as performing work that requires the speed of psychomotor reactions.

Capsules